Matrix matters

Circulation

Volumn 102, Issue 16, 2000, Pages 1874-1876

  Libby, Peter ^a   Lee, Richard T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cells; Editorials; Extracellular matrix; Metalloproteinases

Indexed keywords

CATHEPSIN S; CD147 ANTIGEN; CYSTATIN C; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0034680304     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.16.1874     Document Type: Review

References (15)

1. Cell adhesion molecules, signal transduction and cell growth
2. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
3. Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells
4. Matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure
5. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A: A kinetic study
6. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
7. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function
8. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
9. Matrix metalloproteinase inhibition blocks progression of heart failure
10. Loss of myocardial collagen produces cardiac dysfunction
11. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts
12. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
13. Targeted deletion of MMP-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction
14. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases
15. Cystatin C deficiency in human atherosclerosis and aortic aneurysms